The Fund seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Pharmaceutical 25 Index, which includes common stocks of companies in the pharmaceutical industry. The Fund normally invests at least 80% of its assets in securities of the Index.